STS Administration on Coronavirus Disease (COVID-19) Patients in Critical Care (H4COVID)
COVID-19, Virus Diseases, Corona Virus Infection
About this trial
This is an interventional treatment trial for COVID-19 focused on measuring COVID-19, SARS-CoV-2, Hydrogen Sulfide, Sodium Thiosulfate, Hydrogen Sulfide donor
Eligibility Criteria
Inclusion Criteria:
- Age equal to or older than 18 years
- Both genders
- For women of childbearing potential, they must use or be willing to use a dual contraceptive method during the study.
- Written consent statement provided by the patient or his / her legal representative in case patients are unable to consent.
- Confirmed COVID-19 disease
- WHO-CPS 7 to 9
- Hospitalization in Intensive Care Unit
- Serum H2S levels less than 140 μM
Exclusion Criteria:
- Age less than 18 years
- Denial of written consent
- Decision not to resuscitate
Sites / Locations
- General Hospitan of Athens KAT 2nd Department of ICURecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
No Intervention
Experimental
Experimental
Standard Treatment
One intravenous 12.5 gr STS - Treatment Group 1
Three intravenous doses of 12.5 gr STS - Treatment Group 2
The standard treatment includes the application of mechanical ventilation and / or support with the administration of inotropes and / or extracorporeal oxygenation (ECMO) and the intravenous administration of fluids and dexamethasone. The administration of any other immunosuppressive therapy, including tocilizumab and / or antimicrobials at the discretion of the therapists, is permitted.
Patients will receive standard treatment and one intravenous (iv)12.5 gr STS in 60 minutes continuous intravenous infusion. STS is dissolved in a final volume of 100ml N/S 0.9% w/v,
Patients will receive standard treatment and three intravenous doses of 12.5 g STS. STS is dissolved in a final volume of 100ml N/S 0.9% w/v. Each dose will be given in 60 minutes of continuous intravenous infusion with 48 hours intervals between each dose.